CJ
RARE icon

Caitlin John’s Ultragenyx Pharmaceutical RARE Stock Holding History

Caitlin John’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105 Hold
5
– – ﹤0.01% 914
2025
Q4 		$115 Hold
5
– – ﹤0.01% 903
2025
Q3 		$150 Buy
+5
New +$150 ﹤0.01% 851
2025
Q1 		– Sell
-5
Closed -$210 – 633
2024
Q4 		$210 Hold
5
– – ﹤0.01% 817
2024
Q3 		$244 Hold
5
– – ﹤0.01% 803
2024
Q2 		$206 Buy
+5
New +$213 ﹤0.01% 805

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Caitlin John's RARE Position: Q1 2026 in Review

Caitlin John held its Ultragenyx Pharmaceutical (RARE) position steady in Q1 2026 at 5 shares worth $105. The position accounts for ﹤0.01% of the portfolio, ranked #914.

Caitlin John first reported a position in RARE in Q2 2024 and has held it in 6 quarters since. The position peaked at $244 in Q3 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Caitlin John held 5 shares of Ultragenyx Pharmaceutical worth $105 as of Q1 2026.
  • Caitlin John left its Ultragenyx Pharmaceutical share count unchanged in Q1 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Caitlin John's portfolio in Q1 2026, its #914 holding.
  • Caitlin John first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and has held it in 6 quarters since.
  • Caitlin John's Ultragenyx Pharmaceutical position peaked at $244 in Q3 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.